Detail akcie DiaSorin online

Business Summary: DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
Financial Summary: BRIEF: For the six months ended 30 June 2025, DiaSorin SpA revenues increased 5% to EUR619.3M. Net income applicable to common stockholders increased 4% to EUR99.4M. Revenues reflect North America segment increase of 10% to EUR307.9M, Europe segment increase of 5% to EUR216.5M. Net income was partially offset by non recurring amount increase from EUR2.2M to EUR10.1M (expense), Other Development and Research increase of 7% to EUR36.5M (expense).